US EditionPublished • loading... • Updated
Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases
- Kaigene Inc. has entered into an exclusive global licensing agreement with Celltrion Inc. for antibody therapeutics KG006 and KG002.
- Under the agreement, Kaigene will receive an $8 million upfront payment and can earn up to $736 million in milestone payments, including $11 million for Phase 1 trial initiation.
- Celltrion will develop and commercialize KG006 globally, excluding Greater China and Japan, while holding worldwide rights for KG002.
- KG006 is a next-generation FcRn inhibitor, and KG002 is a first-in-class antibody that selectively degrades autoantibodies.
Insights by Ground AI
47 Articles
47 Articles
Kingsport Times-News+46 Reposted by 46 other sources
Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases
Celltrion will develop and commercialize Kaigene's nonclinical-stage antibody assets, KG006 and KG002, under an exclusive licensing agreement.Kaigene will receive $8M upfront payment and up to $736M in potential milestone payments, including $11M in near-term milestones through the initiation of Phase…
Coverage Details
Total News Sources47
Leaning Left6Leaning Right6Center13Last UpdatedBias Distribution52% Center
Bias Distribution
- 52% of the sources are Center
52% Center
L 24%
C 52%
R 24%
Factuality
To view factuality data please Upgrade to Premium
